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A B S T R A C T
Introduction: Stem cell-derived cardiac myocytes are potential sources for testing cardiocytoprotective molecules
against ischemia/reperfusion injury in vitro.
Materials and methods: Here we performed a systematic analysis of two different induced pluripotent stem cell
lines (iPSC 3.4 and 4.1) and an embryonic stem cell (ESC) line-derived cardiac myocytes at two different de-
velopmental stages. Cell viability in simulated ischemia/reperfusion (SI/R)-induced injury and a known cardi-
ocytoprotective NO-donor, S-nitroso-n-acetylpenicillamine (SNAP) was tested.
Results: After analysis of full embryoid bodies (EBs) and cardiac marker (VCAM and cardiac troponin I) positive
cells of three lines at 6 conditions (32 different conditions altogether), we found significant SI/R injury-induced
cell death in both full EBs and VCAM+ cardiac cells at later stage of their differentiation. Moreover, full EBs of
the iPS 4.1 cell line after oxidative stress induction by SNAP was protected at day-8 samples.
Conclusion: We have shown that 4.1 iPS-derived cardiomyocyte line could serve as a testing platform for car-
diocytoprotection.
1. Introduction
There is still no cardioprotective drug on the market after more than
3 decades of intensive research [1], therefore, search for therapeutic
agents to alleviate myocardial ischemia/reperfusion injury is of great
importance [9,38].
In preclinical drug testing, in vitro cardiac myocyte-based platforms
developed from cardiomyoblast lines, neonatal or adult primary car-
diomyocytes are frequently and traditionally used experimental tools in
screening for cardioprotective drugs [38]. Despite their advantages for
pharmaceutical applications, these assays face severe challenges, in-
cluding limited proliferation capacity, uncontrolled stress during cell
isolation, low throughput nature and poor predictability towards in vivo
efficacy [49]. Additionally, taking into account of 3R (replacement,
reduction and refinement) principles, a more appropriate cell source is
highly desirable [21].
Embryonic stem cells (ESC) with human origin offer a virtually
unlimited number of cells capable of differentiating towards cardiac
lineage [50], however, ethical and immunological concerns sur-
rounding human ESCs impede their clinical or research application [48]
as well. The discovery of induced pluripotent stem cells (iPSC) by the
reprogramming of somatic cells has provided a new alternative plur-
ipotent stem cell (PSC)-derived cell systems without the above-
mentioned limitations [41,42,53]. IPS cells can be derived from human
somatic cells; therefore, they can be promising in vitro platform and also
tool for cell therapy as well [7,22,37,39]. Although, iPSC-derived
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cardiac myocytes have been used for in vitro drug safety testing, there is
no data on their application for modelling ischemia/reperfusion injury
and testing cardioprotection.
In contrast to the encouraging results and the enormous potential of
iPSC-derived cardiomyocytes, numerous technical obstacles need to be
overcome. These include the development of efficient and reliable
protocols for differentiation and strategies for cardiomyocyte selection
[18,27]. Application potential of iPSC-derived cardiac myocyte in heart
regeneration and repair is still limited in clinical trials, where the
protection of them in the unfavourable ischemic myocardial micro-
environment will be indispensable [28]. Therefore, characterization of
iPSC-derived cells in a simulated ischemia/reperfusion test platform
and testing potential cardioprotective candidate compounds for is-
chemic heart diseases has a great importance.
Thus, in this study we performed a systematic analysis of 2 different
mouse iPSC lines and an embryonic stem cell line at two stages of
cardiac differentiation, with and without oxidative stress conditions,
respectively. In each series full embryoid bodies and cardiac marker
positive cell were implemented to study the response of cells to simu-
lated ischemia/reperfusion (SI/R) and cardiocytoprotection of NO-
donor SNAP.
2. Materials and methods
The investigation conforms to the Guide for the care and use of
laboratory animals published by the US National Institutes of Health
(NIH publication No. 85-23, revised 1996) and was approved by the
Ethics Committee at the University of Szeged.
Materials for the cell culture and sample preparation, unless
otherwise indicated were purchased from Thermo Fischer Scientific Inc.
(Carlsbad, USA).
2.1. Cell culture
The HM1 mouse ESCs [36] at passage 19, was kindly provided by
Roslin Institute, UK. The iPS 3.4 and iPS 4.1 mouse iPSC lines were
provided by Prof Roger Pedersen (University of Cambridge, UK). The
ESC and iPSC lines were cultured and maintained under feeder-free
conditions in KOSR+2i media (KnockOut™ DMEM supplemented with
15% KnockOut™ Serum Replacement, 1mM Na-Pyruvate, 0.1mM non-
essential amino acids, 0.1mM 2-mercaptoethanol, 4 mM GlutaMAX™,
50 U/ml penicillin/streptomycin, 2000 U/ml Leukemia Inhibitory
Factor (LIF) (Millipore), 5 μg/ml Insulin (Sigma), 1 μM of the mitogen-
activated protein kinase inhibitor PD0325901 (StemGent) and 3 μM of
the glycogen synthase kinase-3 inhibitor CHIR99021 (StemGent) [12].
When in culture, the cells were maintained at 37 °C humidified air
Fig. 1. Cardiac differentiation and experimental protocol of simulated ischemia and reperfusion in mouse ESC- or iPSC-derived embryoid bodies.
(A) Pluripotent stem cells of mouse origin (ESC or iPSCs) were dissociated and EBs were generated in hanging drops. After three days the formed EBs were further
differentiated to generate cardiomyocytes by culturing them individually in 24-well plates for 8 and 16 days. EBs were characterized by immunocytochemistry (ICC)
and RT-qPCR at day 8 or 16. The experiment was also carried out under oxidative stress condition induced by 24 h H2O2 treatment before differentiation.
(B) EBs were exposed to 150min hypoxia followed by 120min reperfusion at day 8 or day 16. Cells were treated with vehicle or NO-donor SNAP during simulated
ischemia. Cell viability of full EBs was assessed by propidium iodide staining. Cell viability of VCAM-1 or cTnI positive cells was evaluated after immunolabelling
with flow cytometry.
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containing 5% CO2 in incubator and passaged every third day using
0.25% trypsin-EDTA.
2.2. In vitro cardiac differentiation
For cardiac differentiation, embryoid bodies (EBs) were generated
using the Hanging Drop method. Briefly, one day before EB plating the
2i media was changed to LIF-free basic ESC media (DMEM-GlutaMax,
15% (v/v) ESC qualified FCS (fetal calf serum, SLI Ltd), 0.1 mM non-
essential amino acids, 0.1mM 2-mercaptoethanol, 50 U/ml penicillin/
streptomycin). Single cell suspensions were obtained by dissociating
iPSCs with 0.25% trypsin-EDTA (day 0). The cells were diluted in
4× 104 cells/ml and 20 μl droplets (800 cells/droplet) were pipetted
onto the lid of low attachment Petri dish in differentiation medium
(basic ESC medium without LIF). The cells were allowed to aggregate
using gravity by inverting the lid over the dish. On day 3, individual
EBs were plated into a well of a 24-well plate containing coverslips
coated with 0.1% gelatin. Differentiation medium was changed every
second day, the number of contracting cardiomyocytes was con-
tinuously observed.
2.3. Oxidative stress assay
One series of iPSCs were treated for 24 h by supplementing the
media with 0.01 μM or 0.05 μM H2O2 (Sigma) for oxidative stress in-
duction. After 24 h of treatment stem cells were harvested and differ-
entiated as described above. The differentiation was monitored after 8
and 16 days (Fig. 1, panel A).
Beating rates were calculated at day 8 and 16, by counting the
beating EBs on a 24-well plate. In one experiment three parallels
(n=72) were counted and four independent experiments were ana-
lysed.
2.4. Immunocytochemistry
Samples were fixed with 4% PFA (30min, RT), then permeabilized
with 0.1% Triton-X 100, and 0.1% bovine serum albumin (BSA)-con-
taining PBS. Cells were screened for the expression of cardiac differ-
entiation markers by incubation with the primary antibodies against:
Nkx2–5, Troponin T, VCAM-1, Phalloidin (labelling of F-actin) and
Desmin (overnight, 4 °C). Samples were then incubated with the ap-
propriate fluorescent secondary antibodies (1 h, RT). For counter-
staining DAPI (20min, RT) was used. The details of antibodies and
dilutions are listed in Table 1. The cells were observed under fluor-
escent microscope equipped with 3D imaging module (AxioImager
system with ApoTome, controlled by AxioVision 4.8.1 Microscope
software; Carl Zeiss).
2.5. Reverse transcription-qPCR (RT-qPCR) analysis
Total RNA was isolated from cells using RNeasy Plus Mini Kit
(Qiagen). SuperScript VILO cDNA Synthesis Kit was used according to
the manufacturer's instructions.
Primers for genes (see Table S1) were designed using the Primer3
software [34]. To avoid interfering secondary DNA structures mFOLD
software was utilized [55], and the specificity of the primers was ver-
ified by Primer-BLAST [52]. 6 selected genes and Gapdh as reference
were used for RT-qPCR analysis (Table 2). Each RT-qPCR reaction
contained 5 ng RNA equivalent cDNA template, 400 nM of each primer
and 50% SYBR Green JumpStart Taq ReadyMix (Sigma Aldrich) in a
total volume of 15 μl. PCR reactions were set up using QIAgility liquid
handling robot and were performed on a Rotor-Gene Q cycler (Qiagen).
The cycling parameters were as follows: 94 °C for 3min initial dena-
turation followed by 40 cycles of 95 °C for 5 s, 60 °C for 15 s and 72 °C
for 30 s. Melting curve analysis and agarose gel electrophoresis con-
firmed the specificity of the primers. Data of three replicates were
analysed using the Relative Expression Software Tool 2008 V2.0.7 [30].
2.6. Simulated ischemia/reperfusion (SI/R) treatment of mouse ESC- and
iPSC-derived cardiomyocytes
The protocol of SI/R experiments was based on Gorbe et al. [14],
whereas both mouse ESC-derived and iPSC-derived embryoid bodies
(EBs) on either day-8 or -16 of differentiation were tested under nor-
moxia or were subjected to SI (Fig. 1, panel B).
In the normoxic groups, the growth medium of cells was replaced
with a normoxic solution (in mM: NaCl 125, KCl 5.4, NaH2PO4 1.2,
MgCl2 0.5, HEPES 20, glucose 15, taurine 5, CaCl2 1, creatine 2.5, BSA
0.1%, pH 7.4, 310mOsm/l) [20] and cells were incubated under 95%
air and 5% CO2 tension (150min, 37 °C). Regarding SI groups, EBs were
exposed to hypoxia (0,04% O2, 5CO2, 95% N2) by incubating the cells
in hypoxic solution (in mM: NaCl 119, KCl 5.4, MgSO4 1.3, NaH2PO4
1.2, HEPES 5, MgCl2 0.5, CaCl2 0.9, Na-lactate 20, BSA 0.1%,
310mOsm/l, pH=6.4) [20] and were kept in the multigas incubator
(150min, 37 °C).
The experimental setup consisted the following groups: 1, normoxic
(covered by normoxic solution); 2, simulated ischemia (vehicle) and 3,
simulated ischemia supplemented with SNAP (S-nitroso-N-acetyl-D,L-
penicillamine, 1 μM). All treatments were followed by 120min simu-
lated reperfusion in growth medium and superfusion with 95% air and
5% CO2 at 37 °C. At the end of SI/R experiments, cell death of EBs was
assessed by using propidium iodine (PI) assay combined with
PI+ digitonin staining (total cell count). In another set of EBs, the ratio
of cell death was also determined using Live/Dead assay after SI/R
followed by immunolabelling of cardiac markers and flow cytometric
analysis (Fig. 1, panel B).
In the second set of experiments, all procedures were performed on
accelerated cardiac differentiation (H2O2 induced) EB series (Fig. 1,
panels A and B).
2.7. Assessment of cell death in full embryoid bodies
For the assessment of cell death in full EBs, PI viability assay was
performed in combination with total cell count determination
(PI+ digitonin staining). Briefly, medium of EBs was removed and cells
were washed twice with warm D-PBS (Sigma). Then cells were
Table 1
Antibodies used for immunocytochemistry.
Antibody Dilution Company (CatN)
Primary antibodies Anti-VCAM-1 1:250 Abcam (ab134047)
Anti-Nkx2-5 1:100 Santa Cruz Biotechnology (sc-14033)
Anti-cardiac Troponin T 1:200 Abcam (ab33589)
Anti-CD106 1:200 BioLegend (BZ-105710)
Anti-Desmin 1:100 DAKO (M0760)
Secondary antibodies Alexa Fluor 488 donkey anti-mouse IgG 1:2000 Thermo Fisher Scientific Inc. (A-21202)
Alexa Fluor 488 donkey anti-rabbit IgG 1:2000 Thermo Fisher Scientific Inc. (A-21206)
Other DY-554-Phalloidin 1:500 Dyomics (554-33)
J. Pálóczi, et al. Vascular Pharmacology 133–134 (2020) 106781
3
incubated with PI solution (50 μM) and plates were kept in a dark place
(7min, RT). The fluorescence intensity of each EB was detected by
using a fluorescent plate reader. As for the PI+ digitonin assay, PI
(50 μM) and digitonin (500 μM) were added into the wells in order to
estimate total cell number in each well. Cells were then incubated with
PI+ digitonin solution (7min, RT). Then fluorescence intensity was
measured at 544em/620ex. Background fluorescence intensity (dye
control) was subtracted from the fluorescence intensity of each well
after staining, and the average intensity of each group was plotted.
2.8. Assessment of cell death by flow cytometry
For the determination of cardiac cell death in EBs, Live/Dead assay
was used (Life technologies, L10120) Reagents were prepared ac-
cording to the manufacturer's instruction. At the end of simulated re-
perfusion, cells were washed twice with warm D-PBS, then they were
incubated Live/Dead reagent in dark (30min, RT). Subsequently, cells
were washed again with D-PBS and processed towards flow cytometry.
2.9. Immunolabelling of VCAM-1 (CD106) positive cell population of EBs
for flow cytometry
EBs were detached by adding collagenase type IV solutions
(0.125mg/ml) into the wells, because of avoiding destruction of cell
surface marker. Cell suspensions were collected into Eppendorf tubes
and centrifuged at 400×g (5 min, 4 °C). Then cells were resuspended
and incubated with Alexa Fluor 488 anti-mouse CD106 (also known as
vascular cell adhesion molecule 1 or VCAM-1) antibody (BioLegend BZ-
105710) at the dilution of 1:200 (1 h, 4 °C). After the immunolabelling
of VCAM-1, cells were washed and centrifuged at 400×g for (5min,
4 °C) then they were resuspended in PBS containing 2% paraf-
ormaldehyde (PFA) and fixed for 10min at room temperature.
Subsequently, cells were washed with PBS and centrifuged again at
400×g (5 min, 4 °C). The supernatant was discarded and the cells were
resuspended in 1ml PBS for flow cytometry. Investigations were carried
out by using a PARTEC TM FACS analyser. For each experiment, 20,000
events were counted and analysed in the appropriate size range. Gating
strategy was chosen according to the unstained controls. Besides CD106
positive events, dead cells were also counted and analysed.
2.10. Immunolabelling of cTnI positive cell population of EBs for flow
cytometry
The detection of troponin I, cardiac (cTnI) positive cells required the
same steps as it was mentioned above. Regarding the digestion step,
trypsin solution (0.25%) was used to detach EBs. After the supernatant
was removed, the cells were resuspended and fixed in 2% PFA solution
(10min, RT). After the washing step with PBS, samples were incubated
with Anti-Cardiac Troponin I (cTnI) antibody (abcam, ab19615) at
1:100 dilution (overnight, 4 °C). Primary anti-cTnI antibodies were di-
luted in PBS solution containing Triton-X (1%). On the following day,
cells were washed with PBS and centrifuged at 400×g (5 min, 4 °C).
Then cells were resuspended and incubated with secondary antibody
(goat anti-mouse-TRITC) at a dilution of 1:500 (30min, RT).
Subsequently, cells were washed with PBS. The supernatant was dis-
carded and cell pellets were resuspended in PBS. The cTnI positive
fraction of EBs was analysed by flow cytometry as described above. The
ratio of dead cells was also counted and analysed in the same manner.
For CD106 and cTnI co-staining studies, samples were immunolabelled
for CD106, then following fixation, cells were incubated with primary
anti-cTnI antibodies and processed as described above.
2.11. Statistical analysis
Results are expressed as mean ± SEM. One-way analysis of var-
iance (ANOVA) followed by Tukey post-hoc tests were used to analyse
differences in mean values between the experimental groups.
Differences were considered significant at p < 0.05.
3. Results
3.1. Characterization of cardiac-differentiated ESCs and iPSCs
To obtain myocardial cells for the investigation of ischemia and
reperfusion, we have performed directed differentiation of a mouse
ESC- and two iPSC-lines. The cultures were first characterized with
comparative immunocytochemistry at two time points of cellular dif-
ferentiation (day 8 and 16). The fluorescent signal of each cardiac
marker (NKX2-5, Troponin T, VCAM-1 and F-actin labelled with
Phalloidin) was detected by fluorescent microscopy in all the three
lines. The expression of cardiac markers was elevated from day 8 to 16
(Fig. 2), which demonstrates the progress of cardiac differentiation.
Although the early cardiac precursor marker NKX2-5 was more pro-
minent in day 8 samples, it was still observable in several cells at day
16. In line with this the later cardiac markers Troponin T and VCAM-1
were more prominent in day 16 samples, however no major difference
was detected among the examined iPSC lines (Fig. 2). The cardiac
specificity of VCAM-1 was verified by Desmin counterstaining in mouse
ESC-derived embryoid bodies at day-8 and 16. Both cardiac markers
showed higher expression at later stage of differentiation (day-16) and
showed co-expression at both differentiation stages (Supplementary
Fig. S1). To further investigate the cardiac specificity of VCAM-1, an-
other series of experiments was performed by fluorescence-activated
cell sorting (FACS). Mouse ESC-derived cells from HM1 strain
Table 2
Primers used for RT-qPCR analysis.
Symbol Description Gene ID Fwd and Rvs primer PCR product (bp)
Nkx2-5 NK2 homeobox 5 18091 ACACCCACGCCTTTCTCAGT 74
AGGTCCCCAGACGCCA
Myh6 Myosin, heavy polypeptide 6, cardiac muscle, alpha 17888 CTACGCCTTCGTCTCTCAGG 80
AGGCACTATCAGTGGCCAAG
Flt1 FMS-like tyrosine kinase 1 14254 CCTGTCACCACAATCACTCC 172
GAGTCAGCCACCACCAATGT
Pecam1 Platelet/endothelial celladhesion molecule 1 18613 CGATTGTAGCCACCTCCAAG 132
TGTTGACCATGATGCTACTGG
Notch1 Notch1 18128 ACTGCGAGAACAACACACCT 104
GAAGCCAGGTGGACACAGAC
Vwf Von Willebrand factor 22371 GGCAAGAGAATGAGCCTGTC 122
TAGAGTCCTTGGGAGGCGTA
Gapdh⁎ Glyceraldehyde-3-phosphate dehydrogenase 14433 AATGTGTCCGTCGTGGATCT 79
CCTGCTTCACCACCTTCTTG
⁎ The reference gene used in the study.
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underwent flow cytometric analysis to determine the ratio of VCAM-1+
and cTnI+ cells at day 8 and 16. We found a notable increase in
number of VCAM-1+/cTnI+ cells in parallel with the stage of differ-
entiation (32% vs. 71%), indicating the high cardiac specificity of
VCAM-1 (Supplementary Fig. S2). Further validation of cardiac speci-
ficity of VCAM-1 was performed in premature hearts of mouse embryos.
3.2. Validation of cardiac specificity of VCAM-1 in premature hearts
Ultrasound imaging of post-coital female Bl6 mice was applied to
reveal pregnancy and follow up embryonic development
(Supplementary Figs. S3 and S4). At day 12.5 of mouse embryonic
development (E12.5), mice were anesthetized by isoflurane with an
initial rate of 5% and a maintained by 2%. The abdominal cavity was
opened and the uterus was excised and put into phenol red free DMEM.
Mouse embryos were gently isolated by removing the remnant part of
uterus, the decidua and the yolk sac. Finally, the amniotic sac was re-
moved as well. Premature hearts were carefully isolated and ventricles
were collected into Eppendorf tubes containing DMEM supplemented
with collagenase IV (0,125mg/ml). Then ventricles were digested at
37 °C with gentle agitation for 20–30min. Then cells were centrifuged
at 400×g for 5min at 4 °C. Pellets were resuspended and incubated in
PBS solution containing 2% bovine serum albumin supplemented with
Alexa Fluor 488 anti-mouse CD106 antibody at the dilution of 1:200 for
1 h at 4 °C. After a subsequent washing step, cells were centrifuged
again at 400×g for 5min at 4 °C then resuspended in 2% PFA solution
and fixed for 10min at room temperature. Subsequently, cells were
washed and centrifuged at 400×g for 5min at 4 °C. Supernatant was
discarded and cell pellets were resuspended in 1ml PBS for analysis.
Flow measurements were carried out by using a flow cytometer
Fig. 2. Comparative immunocytochemical characterization of strain HM1; iPS 3.4 and iPS 4.1 at stage day 8 and 16.
Fluorescence images are shown with fluorescence signals for DAPI (blue), cardiac marker (NKX2–5, Troponin T, VCAM-1) (green) and Phalloidin (red) labelled F-
actin immunoreactivity. Scale bars= 50 μM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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(Supplementary Fig. S3). First, we evaluated the specificity of VCAM1
during in vivo cardiac differentiation. To examine the specificity of
VCAM1 expression, we performed flow cytometry analysis on prenatal
cardiac cell population of collected hearts of E12.5 mouse embryos. The
VCAM1+ subpopulation in embryonic hearts resulted in 52% of the
intact cell population (see Supplementary Fig. S4, panel D).
3.3. Cell death of ESC- and iPSC-derived EBs and cardiac cells after
simulated ischemia/reperfusion injury
To investigate the ischemic tolerance of mouse ESC- and iPSC-de-
rived cardiomyocytes, EBs were subjected to 150min simulated
ischemia followed by 120min reperfusion (SI/R). One of the SI groups
was administered with cytoprotective NO-donor SNAP to test whether
SNAP can attenuate the detrimental effects of SI/R in our model. Cell
viability assays were performed immediately after reperfusion to de-
termine the ratio of dead cells.
While tendency to increased cell death was observed only for ESC-
derived cells in the vehicle-treated simulated ischemic group of full EBs
on day-8, on day-16 the reduction was significant for ESC and iPS 3.4
lines (Fig. 3A, B). A similar tendency was observed in viability of
VCAM-1+ cells both at day 8 and 16, (Fig. 3C, D), however, there were
no significant differences between normoxic vs SI and SI vs SI treated
SNAP groups. SI/R did not influence cell viability in cTnI+ populations
of both age cohorts (Supplementary Fig. S5). In summary, full EBs re-
sponded to SI/R injury at their later stage of differentiation, meanwhile
cytoprotective effect of SNAP was not observed in any tested series
(Fig. 3A).
3.4. Effect of oxidative stress on cardiac differentiation
In a further experiment, we investigated if oxidative stress accel-
erates the process of cardiac differentiation. First of all, the beating rate
of EBs were compared as a sign of cardiac differentiation. As a result,
the H2O2 induced oxidative stress increased the number of beating EBs
on a concentration dependent manner in all the three cell lines (Fig. 4).
Interestingly, the 0.01 μM H2O2 treatment significantly increased the
number of beating EBs on day 8, while this difference was not sig-
nificant when 0.05 μM concentration was used. On day 16 this effect
could not be further observed as the beating rate of all control and
oxidative stress treated groups reached the plateau (Fig. 4).
Next, we investigated if the expression of cardiac tissue-specific
genes reflects the differences observed for the beating rate. Expression
of early cardiac lineage marker Nkx2-5 showed the highest increase at
day 8 with both H2O2 concentrations in all cell lines, while at day 16 it
decreased but was still significantly upregulated (Fig. 5). Myosin heavy
chain 6 (Myh6) showed a robust increase in both time points and its
peak was as well at day 8. Furthermore, we observed significant dif-
ferences between the cell lines; the H2O2 treatment could induce the
Myh6 expression in both iPSC lines, but not in the ESC line (Fig. 5). For
platelet/endothelial cell adhesion molecule 1 (Pecam1) a relatively
stable expression was observed throughout differentiation (Supple-
mentary Fig. S6). The expression of FMS-like tyrosine kinase 1 (Flt1)
and Notch1 increased with the progression of the differentiation in all
Fig. 3. Effect of simulated ischemia/reperfusion injury on cell viability of mouse ESC- or iPSC-derived embryoid bodies.
Embryoid bodies (A, B) and VCAM-1+ (C, D) subpopulation of mouse ESC- or iPSC-derived cells were subjected to simulated ischemia (SI) and reperfusion at day 8
and 16 of differentiation. Cells were treated with vehicle or NO-donor SNAP during SI. Reperfusion was followed by cell viability assay. Data are normalized to
normoxic control and expressed as mean ± SEM; ⁎p < 0.05 one-way ANOVA, followed by Tukey’s multiple comparisons test compared to normoxic group,
#p < 0.05 one-way ANOVA, followed by Tukey’s multiple comparisons test compared to SI+ vehicle treated group, n=10–12. Flow cytometric data obtained from
three independent measurements.
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lines, which was attenuated by the oxidative stress treatment. Von
Willebrand factor (Vwf1) showed a similar trend, except on day 16
when the oxidative stress treatments resulted a misregulation (Sup-
plementary Fig. S6).
3.5. Cell death of accelerated differentiation ESC- and iPSC-derived EBs
and cardiac cells after simulated ischemia/reperfusion injury
When oxidative stress was applied before differentiation, SI/R sig-
nificantly induced cell death in iPS4.1 full EBs, which was abolished
with application of NO-donor cardioprotective SNAP at day 8. In ESC
and iPS3.4-derived full EBs at day 8 showed only slight tendency to that
pattern (Fig. 6A). In contrast, increased cell death was shown at day 8
for the group of VCAM-1+ cells of all lines (Fig. 6C). At day 16, in ESC
and iPS3.4-derived full EBs SI/R resulted significant cell death, but not
in VCAM-1 positive lines (Fig. 6B, D). The presence of cytoprotective
SNAP was able to reduce excessive cell death only in VCAM-1+ iPS4.1
cells at day 8 (Fig. 6).
4. Discussion
In the present study, we aimed to establish an ESC and iPSC-derived
cardiac myocyte-based in vitro drug screening platform which is able to
assess the ischemic tolerance of differentiating cardiac cells. This is the
first systematic analysis of stem cell-derived cardiac myocytes to SI/R
induced cell death and cardiocytoprotection. After analysis of full EBs
and cardiac marker positive cells of three cell lines at 6 conditions (32
different conditions altogether), we conclude that the severity of SI/R
injury-induced cell death increased in both full EBs and VCAM+ car-
diac cells at a later stage of their differentiation. Moreover, full EBs of
the iPS 4.1 cell line after accelerated differentiation at Day 8 was
protected by SNAP, showing that this setting could serve as a testing
platform for cardiocytoprotection.
Differentiated cardiomyocyte-based platforms have an emerging
role in modelling of cardiac tissue and developing drug screening assays
for pharmaceutical research [21]. The primary neonatal cardiomyo-
cytes may be used for SI/R models [11,13], and adult cardiac myocytes
are appropriate for studying individual cells [10,40]. However, extra-
cellular matrix proteins are required for maintenance and function of
Fig. 4. Effect of oxidative stress on the number of beating EBs.
Mouse ESCs and iPSCs were treated for 24 h by supplementing the culture media with 0.01 or 0.05 μM H2O2 or untreated (control). Pluripotent cells were dissociated
and EBs were generated in hanging drops. After three days the formed EBs were further differentiated to generate cardiomyocytes by culturing them individually in
24-well plates for 8 and 16 days. The number of beating EBs were counted at day 8 and day 16. Data is presented in the % of the total number of plated EBs (beating
rates) (mean ± SEM; ⁎p < 0.05). Data was collected from 4 independent experiments.
Fig. 5. Expression of cardiac marker genes in EBs after oxidative stress.
Mouse ESCs and iPSCs were treated for 24 h by supplementing the culture media with 0.01 μM (grey bars) or 0.05 μM H2O2 (black bars) or kept without oxidative
stress treatments (white bars). Furthermore, cells were differentiated towards cardiomyocytes and their gene expression pattern was evaluated by RT-qPCR on day 8
and 16. Values are expressed as relative expression (mean ± SEM) normalized to the day 0 control (⁎⁎p≤0.05; ⁎p≤0.1 calculated using Relative Expression
Software Tool).
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adult cardiomyocytes which may influence the cell viability during si-
mulated ischemia-reperfusion [49], and the isolation procedure as well
the maintenance of cell cultures are complicated [47]. Embryo-derived
and reprogrammed pluripotent stem cell lines including ESCs and iPSCs
have been used in combination with biomaterials for tissue engineering
[42,43]. The genotypic and phenotypic features of primary and ESC-
derived cardiac myocytes are very similar [3]. It is well known, that the
cardiovascular progenitor cells (CVPCs) segregate from the mesoderm
compartment in the early phase of development. CVPCs are multipotent
cells that express Nkx2-5, Flk-1, Isl1 and c-KIT, and give rise to en-
dothelial, smooth muscle and cardiac precursor cells (CPCs) as well.
CPCs are the ones which are capable of differentiating towards cardi-
omyocytes and still express NKX2-5 representing an early and selective
marker of this precursor population. CPCs also express GATA4 protein,
a zinc finger transcription factor, which has a role in the activation of
genes related to myocardial differentiation. Further specification and
differentiation of CPCs is marked by the expression of functional sar-
comere- and chamber-specific cardiac proteins (α- and β–MHC, MLC-
2v, ANF) [32,46]. When mouse iPSCs are differentiated in hanging
drops the differentiation follows the above-mentioned lineage. How-
ever, the efficiency and percentage of different subpopulations can vary
in LIF-free conditions without the administration of extra growth fac-
tors and cytokines [25,26,44]. The utilization of ESC-derived cardio-
myocytes would be suitable for drug screening; our work group pre-
viously successfully derived cardiomyocytes from mouse ESC, and also
demonstrated pharmacological cardioprotection in the HM1 line-de-
rived cardiac myocyte-based SI/R model [14,28]. However, ethical
considerations limit the utilization of human ESC-derived platforms.
IPSC-derived cardiomyocyte platforms can overcome these ethical
concerns, but little is known about iPSC-derived cardiomyocytes and
their behaviour in ischemic conditions.
We characterized the cardiomyocytes with comparative im-
munocytochemistry at two time points of cellular differentiation (day 8
and 16) after the directed differentiation of a mouse ESC- and iPSC-
lines. The expression of early cardiac marker NKX2-5 and later marker
Troponin T demonstrated the progress of cardiac differentiation.
VCAM-1 was also included to our study as it was shown previously that
this protein is a potent cell surface marker for robust, efficient and
scalable purification of cardiomyocytes from human ESC and iPSCs
[45]. In accordance with this, mouse ESC-derived cardiomyocytes can
be isolated with almost perfect purity and viability, based on their ex-
pression of VCAM-1 and these cells were furthermore suitable for in
vitro culture [31]. Recently, the proliferation of mouse ESC-derived
cardiomyocytes could be enhanced through VCAM-1 signalling, leading
to an increase in functional myocardial cells in bioengineered tissue
[16]. Nevertheless, there is limited information available on the ex-
pression of this gene in iPSC-derived cardiomyocytes. Accordingly, we
aimed to investigate the cardiac specificity of VCAM-1 in these cells.
The results have shown that VCAM-1 were more prominent in day 16
samples in all the examined ESC and iPSC lines, which confirmed the
previous results. The cardiac specificity of VCAM-1 in mouse ESC-de-
rived EBs was demonstrated by immunocytochemistry and FACS. We
also tested VCAM-1 expression in premature hearts of mouse embryos.
This allowed us to enrich mature cardiomyocyte population of our
samples (VCAM-1+ group of cells) in the further experiments. Based on
the literature, primary cardiomyocytes differentiated from mouse PSCs
are expressing VCAM-1, which are not representing fully matured adult
cardiac cells. Referring to the work of Pontén et al. [31], mouse PSC
derived VCAM-1 positive cardiomyocytes belongs to both atrial and
ventricular compartments and could not be distinguished based on this
Fig. 6. Effect of simulated ischemia/reperfusion injury on cell viability of mouse ESC- or iPSC-derived embryoid bodies induced by 24 h H2O2 treatment during
differentiation.
Embryoid bodies (A, B) and VCAM-1+ (C, D) subpopulation of mouse ESC- or iPSC-derived cells were subjected to simulated ischemia (SI) and reperfusion at day 8
and 16 of differentiation. Cells were treated with vehicle or NO-donor SNAP during SI. Reperfusion was followed by cell viability assay. Data are normalized to
normoxic control and expressed as mean ± SEM; ⁎p < 0.05 one-way ANOVA, followed by Tukey’s multiple comparisons test compared to normoxic group,
#p < 0.05 one-way ANOVA, followed by Tukey’s multiple comparisons test compared to SI+ vehicle treated group, n=10–12. Flow cytometric data obtained from
three independent measurements.
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marker. Although VCAM-1 is reported to be present on multipotent
progenitor cells (MPPs) as well (Together with Flt3) during haemato-
poiesis, due to the different differentiation pathways of lymphoid and
myeloid lineages (reviewed by Lai and Kondo [19]), the activation of
VCAM-1 expression on cardiac progenitors is the result of distinct
processes.
In the next set of experiments, we assessed and compared cardio-
myocyte-based platforms derived from a mouse ESC and two different
iPSC cell lines in SI/R conditions. We have shown that both mouse ESC-
and iPSC-derived full EBs are more sensitive to hypoxia at an advanced
stage of cardiac differentiation, as an overall tendency towards reduced
tolerance to hypoxia at day 16 compared to day 8 was observed. It was
previously shown that murine and human iPSC-derived cardiomyocytes
are particularly sensitive to hypoxia and glucose deprivation [4,54].
Cardiac constructs derived from human iPSc subjected to simulated
ischemia-reperfusion were protected following ischemic pre-
conditioning [5]. The viability patterns of VCAM-1+ cells were similar
to that of the full EBs, as excessive cell death was observed at day 16
compared to day 8.
The cardiac differentiation can be accelerated with temporary ap-
plication of oxidative stress. It seems that upon preceding oxidative
stress treatment the VCAM-1+ fraction of cardiomyocytes become
more vulnerable to the forthcoming ischemia/reperfusion (SI/R)-in-
duced injury as they have decreased viability already at day 8. In
contrast, day 16 VCAM-1+ cardiomyocytes tolerate the SI/R better.
The possible explanation of this observation may be the time dependent
expression of VCAM-1, which shows rapid upregulation in early stage of
cardiomyocyte differentiation, then it slows down by time [6].
Reactive oxygen species (ROS) is generated during normal cellular
metabolism, however the overproduction of ROS can induce oxidative
stress [8]. Besides its toxic effect, it is considered as signalling molecule
as well [15,33]. It was previously reported that ROS promotes differ-
entiation towards both cardiomyogenic and vascular cell lineages in
mouse and human ESCs [17,35]. Free radicals have a distinct role in the
proliferation and differentiation of stem cells in a concentration and
time dependent manner. Even at very low concentration, ROS has a
prominent effect on differentiation; our data clearly show that only
slight changes in concentration of ROS produced by H2O2 was able to
influence gene expression pattern as well as the differentiation. In ad-
dition, the gene expression of major cardiac-, endothelial and smooth
muscle markers as well clearly reflects the effect of oxidative stress on
the cardiac commitment. RT-qPCR experiments have shown that H2O2
treatment significantly increased the expression of the selected cardiac,
smooth muscle and epithelial marker genes. The demanding increase in
the structural protein cardiac Myh6 showed that an intensive cardiac
differentiation occurs in the EBs, which was furthermore promoted by
the oxidative stress treatment in a dose dependent manner. This was in
accordance with the observed increase in the beating rate which is a
morphological attribute of successful cardiac differentiation. One pos-
sible explanation for these findings is that by the H2O2, unsaturated
fatty acids are oxidized, leading to an increased eicosanoid level which
promote the differentiation of pluripotent cells [51]. In conclusion,
although we observed some cell line dependent difference, the lower
dose of H2O2 (0.01 μM) has a triggering effect on cardiac tissue for-
mation. It accelerated the differentiation process and resulted earlier
maturation.
Cardiocytoprotection induced by NO-donor SNAP was also tested in
our SI/R models. Exogenous nitric oxide is cardioprotective in various
myocardial ischemia models. SNAP had a significant cytoprotective
effect against ischemia-reperfusion in primary neonatal, mouse and
human ESC-derived cardiomyocytes [13,14,28]. However, in our ex-
periments SNAP had only a tendency towards cytoprotective effect in
mouse ESC-derived EBs at day 8 and no protection at day 16 or in any
other groups including iPSC-derived EBs. A protective effect of NO-
donor SNAP was detected only in the VCAM-1+ fraction of iPS 4.1 line
when it was previously subjected to oxidative stress. In contrast, NO-
donor nicorandil had protective effects in dystrophin-deficient iPSC-
derived cardiac model via NO-cGMP and KATP-channel dependent me-
chanism [2]. The causes of limited effect in iPSC-based cell platform are
not clearly understood; the expression level of cGMP-PKG changes
during cardiac differentiation in ESC-derived cardiac myocytes [23],
but little is known about the downregulation of NO-cGMP pathway in
iPSC-derived cardiomyocytes. However, the observed cytoprotection by
SNAP in the identical ESC-based platform may highlight the important
differences between the differentiation of ESC- and iPSC-derived car-
diac myocytes.
5. Limitations
PSC-derived cardiac myocytes partially mimic the embryonic stage,
however, several adult-stage genes are also expressed [24]. Accord-
ingly, in our present study using mouse embryonic and iPS cell-derived
cardiac myocytes in EB culture, the expression of VCAM-1 showed early
cardiac differentiation stage and the expression of MYH6 and Troponin-
T showed mature phenotype. Although the present 3D EB culture did
not provide a clean cardiac myocyte lineage differentiation, it is widely
accepted that 3D cultures can mimic better the original tissue en-
vironment ([29]). Moreover, human PSC models may provide data of
more translational value but its significantly higher cost and less ca-
pacity limits its widespread use. In spite of the several limitations de-
scribed above, we believe that the present mouse iPS-based assay pro-
vides a fast and cost effective model to study certain cellular processes
at a fast and cost effective way.
6. Conclusion
In summary, this is the first systematic analysis of stem cell-derived
cardiac myocytes to SI/R induced cell death and cardiocytoprotection.
After analysis of full EBs and cardiac marker positive cells of three cell
lines at 6 conditions (32 different conditions altogether), we conclude
that mouse iPSC differentiation is comparatively similar to the ESC-
based methods. However, from the experimental results and the pub-
lished data it seems that although the pluripotency of mouse ESCs and
iPSCs are very similar, and the differentiation protocols used are exactly
the same, their differentiation capacity can differ. Besides, a high in-
terline variability was detected in the efficiency of cardiac differentia-
tion. Moreover, iPSC derived cardiomyocytes were proved to be less
mature than ECS or foetal tissue derived counterparts. The severity of
SI/R injury-induced cell death increased in both full EBs and VCAM+
cardiac cells at later stage of their differentiation. Moreover, full EBs of
the iPS 4.1 cell line after accelerated differentiation at day 8 was pro-
tected by SNAP, showing that this setting could serve as a testing
platform for cardiocytoprotection.
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